Nanomedicine upscaling for early clinical phases of multimodal cancer therapy
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.
The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct n...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MULTIFUN
Multifunctional Nanotechnology for selective detection and T...
13M€
Cerrado
MAT2010-19326
NANOPARTICULAS MAGNETICAS PARA VECTORIZACION INTRACELULAR Y...
157K€
Cerrado
PID2020-112685RB-I00
NANOMEDICINAS BASADAS EN NANOPARTICULAS PARA INMUNOTERAPIA E...
249K€
Cerrado
PID2019-106845RB-I00
DISEÑO DE NANO Y MICROPLATAFORMAS MAGNETICAS CON EFECTOS SIN...
97K€
Cerrado
NANOTHER
Integration of Novel Nanoparticle based Technology for Thera...
12M€
Cerrado
SAF2017-82223-R
ENTENDIENDO DEL MODO DE ACCION Y LA BIODEGRADACION DE NANOME...
206K€
Cerrado
Información proyecto NoCanTher
Duración del proyecto: 66 meses
Fecha Inicio: 2016-03-08
Fecha Fin: 2021-09-30
Líder del proyecto
FUNDACION IMDEA NANOCIENCIA
Otra investigación y desarrollo experimental en ciencias naturales y técnicas asociacion
TRL
4-5
| 130K€
Presupuesto del proyecto
7M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.
The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.
NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:
• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process.
• Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).
This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).